8-K: Panbela Therapeutics to Transition to OTCQB Market Following Nasdaq Delisting

Panbela Therapeutics will move its stock listing to the OTCQB market after failing to meet Nasdaq's minimum equity requirements.

Summary

• Panbela Therapeutics has announced its common stock will be quoted on the OTCQB market starting April 17, 2024, under the symbol PBLA.
• This move follows the company's delisting from the Nasdaq Stock Market due to not meeting the minimum $2.5 million stockholders' equity requirement.
• The company's board approved the delisting and notified Nasdaq of its intent to file a Form 25 to withdraw its listing.
• Panbela intends to file its own Form 25 to expedite the transition to the OTCQB.
• The delisting from Nasdaq is not expected to impact the eligibility of the company's stock for quotation on the OTCQB.
• The company's pipeline includes assets in clinical trials for familial adenomatous polyposis (FAP), pancreatic cancer, colorectal cancer prevention, and ovarian cancer.
• Ivospemin (SBP-101) has shown a median overall survival of 14.6 months and an objective response rate of 48% in metastatic pancreatic cancer patients.
• Flynpovi has shown statistically significant benefit in delaying surgical events in FAP patients with lower GI anatomy compared to single-agent treatments.

Sentiment

Score: 4

Explanation: The document highlights a significant negative event (delisting from Nasdaq) but also includes positive clinical trial data. The overall sentiment is cautiously negative due to the delisting and the need for future funding.

Positives

• The company's stock will continue to be traded on the OTCQB market, ensuring continued access for investors.
• Ivospemin (SBP-101) has shown promising results in clinical trials for metastatic pancreatic cancer, with a median overall survival of 14.6 months and an objective response rate of 48%.
• Flynpovi has demonstrated a statistically significant benefit in delaying surgical events in FAP patients with lower GI anatomy.
• The company has a pipeline of assets in clinical trials for various cancers, indicating potential for future growth.

Negatives

• The company was delisted from Nasdaq due to not meeting the minimum $2.5 million stockholders' equity requirement.
• The delisting from Nasdaq may negatively impact investor confidence and the company's access to capital.

Risks

• The company's ability to obtain additional funding to execute its business and clinical development plans is a risk.
• The progress and success of the company's clinical development program is uncertain.
• The company's ability to demonstrate the safety and effectiveness of its product candidates is a risk.
• The company relies on a third party for the execution of the registration trial for Flynpovi.
• The company's ability to obtain regulatory approvals for its product candidates is a risk.
• The market acceptance and level of future sales of the company's product candidates is uncertain.
• The cost and delays in product development due to changes in regulatory oversight is a risk.
• The rate of progress in establishing reimbursement arrangements with third-party payors is uncertain.
• The effect of competing technological and market developments is a risk.
• The costs involved in filing and prosecuting patent applications is a risk.
• The company's ability to obtain a listing of its common stock on a national securities exchange is uncertain.

Future Outlook

The company anticipates continued development of its pipeline and is focused on the transition to the OTCQB market. They are looking forward to continued evaluation of their drug candidates.

Management Comments

• Panbela's board of directors approved the delisting of its common stock from The Nasdaq Stock Market LLC.
• Panbela intends to file its own Form 25 in advance of Nasdaqs expected filing of a Form 25, primarily to expedite the transition of its common stock to the OTCQB.

Industry Context

The move to the OTCQB market is a common step for companies that fail to meet the listing requirements of major exchanges like Nasdaq. This is a setback for the company, but it will allow them to continue to operate and develop their pipeline.

Comparison to Industry Standards

• The median overall survival of 14.6 months for Ivospemin in metastatic pancreatic cancer patients is promising when compared to the standard of care of gemcitabine + nab-paclitaxel.
• The objective response rate of 48% for Ivospemin is also notable in the context of pancreatic cancer treatments.
• The >90% prevention of subsequent pre-cancerous sporadic adenomas with Flynpovi versus placebo is a strong result in the context of colorectal cancer prevention.
• The statistically significant benefit of Flynpovi in delaying surgical events in FAP patients with lower GI anatomy is a positive outcome compared to single-agent treatments.

Stakeholder Impact

• Shareholders will experience a change in the trading venue of the company's stock.
• The delisting from Nasdaq may negatively impact investor confidence.
• The company's employees may be affected by the financial challenges and the change in listing.
• The company's customers and suppliers may be impacted by the company's financial situation.

Next Steps

• Panbela will transition its stock listing to the OTCQB market on April 17, 2024.
• The company intends to file its own Form 25 to withdraw its listing from Nasdaq.
• Panbela will continue to develop its pipeline of drug candidates.

Key Dates

Keywords

OTCQB, delisting, Nasdaq, Panbela Therapeutics, PBLA, Ivospemin, Flynpovi, clinical trials, cancer, biopharmaceutical